<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vavilov</journal-id><journal-title-group><journal-title xml:lang="ru">Вавиловский журнал генетики и селекции</journal-title><trans-title-group xml:lang="en"><trans-title>Vavilov Journal of Genetics and Breeding</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2500-3259</issn><publisher><publisher-name>Institute of Cytology and Genetics of Siberian Branch of the RAS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18699/VJ21.090</article-id><article-id custom-type="elpub" pub-id-type="custom">vavilov-3183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>БИОТЕХНОЛОГИЯ В ПОСТГЕНОМНУЮ ЭРУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Biotechnology in the postgenomic epoch  BIOTECHNOLOGY IN THE POSTGENOMIC EPOCH</subject></subj-group></article-categories><title-group><article-title>Использование биоинформационного анализа для определения вероятной причины перекрестного взаимодействия антител к антигенному белку ВПЧ16 L1 с белком ВПЧ6 L1</article-title><trans-title-group xml:lang="en"><trans-title>A bioinformatics approach for identifying the probable cause of the cross-interaction of antibodies to the antigenic protein HPV16 L1 with the HPV6 L1 protein</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6392-9365</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Столбиков</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Stolbikov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иркутск</p></bio><bio xml:lang="en"><p>Irkutsk</p></bio><email xlink:type="simple">valkir5@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7602-7301</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саляев</surname><given-names>Р. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Salyaev</surname><given-names>R. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иркутск</p></bio><bio xml:lang="en"><p>Irkutsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3480-9855</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рекославская</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Rekoslavskaya</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иркутск</p></bio><bio xml:lang="en"><p>Irkutsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Сибирский институт физиологии и биохимии растений Сибирского отделения Российской академии наук;&#13;
Иркутский государственный университет<country>Россия</country></aff><aff xml:lang="en">Siberian Institute of Plant Physiology and Biochemistry of the Siberian Branch of the Russian Academy of Sciences;&#13;
Irkutsk State University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Сибирский институт физиологии и биохимии растений Сибирского отделения Российской академии наук<country>Россия</country></aff><aff xml:lang="en">Siberian Institute of Plant Physiology and Biochemistry of the Siberian Branch of the Russian Academy of Sciences<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>03</day><month>12</month><year>2021</year></pub-date><volume>25</volume><issue>7</issue><fpage>787</fpage><lpage>792</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Столбиков А.С., Саляев Р.К., Рекославская Н.И., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Столбиков А.С., Саляев Р.К., Рекославская Н.И.</copyright-holder><copyright-holder xml:lang="en">Stolbikov A.S., Salyaev R.K., Rekoslavskaya N.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vavilov.elpub.ru/jour/article/view/3183">https://vavilov.elpub.ru/jour/article/view/3183</self-uri><abstract><p>C помощью биоинформационных ресурсов (программ и баз данных) предпринята попытка проанализировать вероятную причину перекрестного взаимодействия антител против ВПЧ16 L1 с антигенными белками ВПЧ6 L1, которое было выявлено при изучении кандидатной вакцины, полученной на основе растительной экспрессионной системы (растений томата). По нашему мнению, наиболее вероятной причиной перекрестного взаимодействия антител с антигенами, принадлежащими к разным патогенным типам вируса папилломы человека (ВПЧ), является сходство антигенных детерминант. В ходе исследования были проанализированы аминокислотные последовательности ВПЧ16 L1 и ВПЧ6 L1, которые использовались при разработке бинарной вакцины против цервикального рака и аногенитальных папилломатозов. Для анализа антигенных детерминант использовались программы BepiPred-2.0: Sequential B-Cell Epitope Predictor, DiscoTope 2.0 Server, SYFPEITHI. В результате исследования вероятных линейных детерминант для В-клеток установили, что у обоих типов ВПЧ белки имеют примерно одинаковое расположение и размер линейных антигенных детерминант, отличие наблюдается только в виде небольших сдвигов в несколько аминокислотных остатков. Однако выявлено некоторое различие в аминокислотном составе эпитопов, поэтому потенциал перекрестного взаимодействия антител с антигенами за счет сходства линейных антигенных детерминант для В-клеток незначителен. Анализ потенциальных трехмерных эпитопов для В-клеток показал, что по сумме различий белки ВПЧ16 L1 и ВПЧ6 L1 не имеют предпосылок для перекрестного взаимодействия антител с антигенами, принадлежащими к двум разным патогенным типам ВПЧ. Анализ вероятных линейных эпитопов для Т-клеток обнаружил у двух белковых последовательностей общую антигенную детерминанту. Согласно рейтингу, составленному программой SYFPEITHI, аминокислотная последовательность AQL(I)FNKPYWL представляет собой вторую, по вероятности, антигенную детерминанту для Т-клеток. При этом аминокислотная последовательность данной детерминанты у ВПЧ16 L1 и ВПЧ6 L1 практически идентична. Отличие имеется лишь по одной позиции, но оно не является критичным в силу сходства физико-химических свойств аминокислот, по которым наблюдается замена в аминокислотной последовательности антигенных детерминант. Исходя из этого можно ожидать умеренно выраженное перекрестное взаимодействие антител к ВПЧ16 L1 с антигенами ВПЧ6 L1.</p></abstract><trans-abstract xml:lang="en"><p>This paper describes an attempt to analyze, with the aid of bioinformatics resources (programs and databases), the probable cause of the cross-interaction of antibodies against HPV16 L1 with antigenic protein HPV6 L1, which has been revealed in the investigation of the candidate vaccine obtained on the base of a plant expression system (tomato plants). In our opinion, the most likely reason for the cross-interaction of antibodies with antigens of different pathogenic HPV types is the similarity of their antigenic determinants. In this work, the amino acid sequences of HPV16 L1 and HPV6 L1 used for the development of a binary vaccine against cervical cancer and anogenital papillomatosis have been analyzed. For the analysis of antigenic determinants, the programs BepiPred-2.0: Sequential B-Cell Epitope Predictor, DiscoTope 2.0 Server and SYFPEITHI have been used. As a result of the analysis of probable B-cell linear determinants (epitopes), it has been found that in both types of HPV the proteins have approximately the same location and size of linear antigenic determinants; the difference is observed only in the form of small shifts in the size of several amino acid residues. However, there are some differences in the amino acid composition of epitopes; therefore, the possibility for cross-interaction of the antibodies with the antigens due to the similarity of linear antigenic determinants for B-cells is very small. The analysis of potential threedimensional epitopes for B-cells has shown that due to little difference between them the HPV16 L1 and HPV6 L1 proteins have no prerequisites for cross-interaction of the antibodies with the antigens belonging to the two different pathogenic HPV types. The analysis of probable linear epitopes for T-cells has revealed a common antigenic determinant in the two protein sequences. According to the rank made with the SYFPEITHI program, the amino acid sequence AQL(I)FNKPYWL is the second most likely antigenic determinant for T-cells. Meanwhile, the amino acid sequences of this determinant in HPV16 L1 and HPV6 L1 are virtually identical. There is a difference in only one position, but it is not critical due to the similarity of the physicochemical properties of amino acids, for which there is a replacement in the amino acid sequence of antigenic determinants. Consequently, some moderate cross-interaction of the antibodies to HPV16 L1 with the antigens of HPV6 L1 may be expected.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вирус папилломы человека</kwd><kwd>ВПЧ6 L1</kwd><kwd>ВПЧ16 L1</kwd><kwd>биоинформационный анализ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>human papillomavirus</kwd><kwd>HPV6 L1</kwd><kwd>HPV16 L1</kwd><kwd>bioinformatics analysis</kwd></kwd-group><funding-group xml:lang="en"><funding-statement>The reported study was funded by Russian Foundation for Basic Research and the Government of the Irkutsk Region, project number 20-44-380001</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandes-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Steben M., Bosch F.X., Dillner J., Joura E.A., Kurman R.J., Majewski S., Muñoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., Sings H.L., James M., Hesley T.M., Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis. 2009;199(7):926-935. DOI 10.1086/597307.</mixed-citation><mixed-citation xml:lang="en">Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandes-Avila M., Wheeler C.M., Perez G., Koutsky L.A., Tay E.H., Garcia P., Ault K.A., Garland S.M., Leodolter S., Olsson S.E., Tang G.W., Ferris D.G., Paavonen J., Steben M., Bosch F.X., Dillner J., Joura E.A., Kurman R.J., Majewski S., Muñoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Lupinacci L.C., Giacoletti K.E., Sings H.L., James M., Hesley T.M., Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis. 2009;199(7):926-935. DOI 10.1086/597307.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jespersen M.C., Peters B., Nielsen M., Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24-W29. DOI 10.1093/nar/gkx346.</mixed-citation><mixed-citation xml:lang="en">Jespersen M.C., Peters B., Nielsen M., Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24-W29. DOI 10.1093/nar/gkx346.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., Schiller J.T., Lowy D.R., Herrero R., Pinto L.A. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate crossprotection. Vaccine. 2011;29(11):2011-2014. DOI 10.1016/j.vaccine.2011.01.001.</mixed-citation><mixed-citation xml:lang="en">Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., Schiller J.T., Lowy D.R., Herrero R., Pinto L.A. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate crossprotection. Vaccine. 2011;29(11):2011-2014. DOI 10.1016/j.vaccine.2011.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kringelum J.V., Lundegaard C., Lund O., Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput. Biol. 2012;8(12):e1002829. DOI 10.1371/journal.pcbi.1002829.</mixed-citation><mixed-citation xml:lang="en">Kringelum J.V., Lundegaard C., Lund O., Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput. Biol. 2012;8(12):e1002829. DOI 10.1371/journal.pcbi.1002829.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Li Z., Song S., He M., Wang D., Shi J., Liu X., Li Y., Chi X., Wei S., Yang Y., Wang Z., Li J., Qian H., Yu H., Zheng Q., Yan X., Zhao Q., Zhang J., Gu Y., Li S., Xia N. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nat. Commun. 2018;9(1):5360. DOI 10.1038/s41467-018-07199-6.</mixed-citation><mixed-citation xml:lang="en">Li Z., Song S., He M., Wang D., Shi J., Liu X., Li Y., Chi X., Wei S., Yang Y., Wang Z., Li J., Qian H., Yu H., Zheng Q., Yan X., Zhao Q., Zhang J., Gu Y., Li S., Xia N. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nat. Commun. 2018;9(1):5360. DOI 10.1038/s41467-018-07199-6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McClements W.L., Wang X.M., Ling J.C., Skulsky D.M., Christensen N.D., Jansen K.U., Ludmerer S.W. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology. 2001;289(2):262-268. DOI 10.1006/viro.2001.1146.</mixed-citation><mixed-citation xml:lang="en">McClements W.L., Wang X.M., Ling J.C., Skulsky D.M., Christensen N.D., Jansen K.U., Ludmerer S.W. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology. 2001;289(2):262-268. DOI 10.1006/viro.2001.1146.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">McLaughlin-Drubin M.E., Münger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009;143(2):195-208. DOI 10.1016/j.virusres.2009.06.008.</mixed-citation><mixed-citation xml:lang="en">McLaughlin-Drubin M.E., Münger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009;143(2):195-208. DOI 10.1016/j.virusres.2009.06.008.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nakagawa M., Greenfield W., Moerman-Herzog A., Coleman H.M. Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines. Clin. Vaccine Immunol. 2015;22(7):679-687. DOI 10.1128/CVI.00149-15.</mixed-citation><mixed-citation xml:lang="en">Nakagawa M., Greenfield W., Moerman-Herzog A., Coleman H.M. Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines. Clin. Vaccine Immunol. 2015;22(7):679-687. DOI 10.1128/CVI.00149-15.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Namvar A., Bolhassani A., Javadi G., Noormohammadi Z. In silico/ in vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Sci. Rep. 2019;9(1):15225. DOI 10.1038/s41598-019-51679-8.</mixed-citation><mixed-citation xml:lang="en">Namvar A., Bolhassani A., Javadi G., Noormohammadi Z. In silico/ in vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Sci. Rep. 2019;9(1):15225. DOI 10.1038/s41598-019-51679-8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rammensee H.G., Bachmann J., Emmerich N.P.N., Bacho O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219. DOI 10.1007/s002510050595.</mixed-citation><mixed-citation xml:lang="en">Rammensee H.G., Bachmann J., Emmerich N.P.N., Bacho O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219. DOI 10.1007/s002510050595.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rekoslavskaya N.I., Salyaev R.K., Stolbikov A.S. The synthesis of main capsid protein of anogenital type HPV6 L1 in plant expression system on the basis of tomato fruits. Doklady Biochemistry and Biophysics. 2021;498(1):193-198. DOI 10.1134/S160767292103008X.</mixed-citation><mixed-citation xml:lang="en">Rekoslavskaya N.I., Salyaev R.K., Stolbikov A.S. The synthesis of main capsid protein of anogenital type HPV6 L1 in plant expression system on the basis of tomato fruits. Doklady Biochemistry and Biophysics. 2021;498(1):193-198. DOI 10.1134/S160767292103008X.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Salyaev R.K., Rekoslavskaya N.I., Stolbikov A.S. Cross-reactivity of antigens and antibodies belonging to different pathogenic types of human papillomaviruses. Doklady Biochemistry and Biophysics. 2017;477(1):372-376. DOI 10.1134/S1607672917060084.</mixed-citation><mixed-citation xml:lang="en">Salyaev R.K., Rekoslavskaya N.I., Stolbikov A.S. Cross-reactivity of antigens and antibodies belonging to different pathogenic types of human papillomaviruses. Doklady Biochemistry and Biophysics. 2017;477(1):372-376. DOI 10.1134/S1607672917060084.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Scherpenisse M., Schepp R.M., Mollers M., Meijer C.J.L.M., Berbers G.A.M. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8(9):e74797. DOI 10.1371/journal.pone.0074797.</mixed-citation><mixed-citation xml:lang="en">Scherpenisse M., Schepp R.M., Mollers M., Meijer C.J.L.M., Berbers G.A.M. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013;8(9):e74797. DOI 10.1371/journal.pone.0074797.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Stolbikov A.S., Salyaev R.K., Rekoslavskaya N.I. Bioinformatics analysis of putative causes for сross-reactive antibodies interacting with antigens derived from various pathogenic human papillomaviruses. Infektsiya i Immunitet = Infection and Immunity. 2020;10(4):695- 706. DOI 10.15789/2220-7619-TBA-1263. (in Russian)</mixed-citation><mixed-citation xml:lang="en">Stolbikov A.S., Salyaev R.K., Rekoslavskaya N.I. Bioinformatics analysis of putative causes for сross-reactive antibodies interacting with antigens derived from various pathogenic human papillomaviruses. Infektsiya i Immunitet = Infection and Immunity. 2020;10(4):695- 706. DOI 10.15789/2220-7619-TBA-1263. (in Russian)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
